Liana F. Zainullina
Research Subjects
Liana F. Zainullina has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Inna P. Tsypysheva
Ufa Institute of Chemistry, Ufa Federal Research Center, Russian Academy of Sciences, Ufa, Russia
4 shared publications - Yulia V. Vakhitova
N.I. Pirogov Russian National Research Medical University
4 shared publications E. I. Farafontova
Russian Academy of Sciences
3 shared publications- Ju. Yu. Firstova
Federal Research Center for Innovator and Emerging Biomedical and Pharmaceutical Technologies
3 shared publications M. S. Yunusov
Russian Academy of Sciences
3 shared publicationsYu. V. Vakhitova
Russian Academy of Sciences
3 shared publications
Latest Publications
- Open Access
- 16 October 2026
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 3,p. 22-34
Approaches to experimental modeling of neuroinflammation in neurodegenerative diseases: part 3 — cell lines
Background. Neuroinflammation is a key pathogenic mechanism in a wide range of central nervous system disorders, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and ischemic stroke. To study the molecular mechanisms of neuroinflammation and screen potential drug candidates, researchers have access to a wide arsenal of in vitro models. Immortalized cell lines remain an indispensable tool at the early stages of pharmacological research; however, their selection requires a critical evaluation of the advantages and limitations of each model. Objective. To conduct a critical analysis of the main immortalized cell lines of microglia, astrocytes, and neurons used for modeling neuroinflammation, and based on this analysis, to formulate recommendations for their selection depending on experimental objectives. Methods. A narrative literature review was performed, summarizing data on the origin, phenotypic characteristics, functional activity, and applications of cell lines. A comparative analysis was conducted for microglial lines (BV-2, N9, N13, EOC, HAPI, HMC3, HMO6), astrocytic lines (U-87, U-251, U-373, A-172, T98G), and neuronal lines (SH-SY5Y, PC-12), with emphasis on their response to inflammatory stimuli, mediator production, and preservation of specific markers. Results. The BV-2 line retains 90 % of genes induced in primary microglia and is considered the "gold standard" for primary screening of anti-inflammatory compounds; however, it exhibits an elevated basal activation level. Spontaneously immortalized lines EOC and HAPI/SIM-A9 are phenotypically closer to primary cells and retain functional phagocytosis. Among human lines, HMO6 demonstrates TREM2-dependent phagocytosis of β-amyloid and the ability for M1/M2 polarization, whereas HMC3 does not express key microglial markers (P2RY12, TREM2) and expresses pericyte markers, which significantly limits its value. Astrocytic lines differ in their sensitivity to IL-1β: U-251 and U-373 show a pronounced response, whereas T98G is resistant. Neuronal lines SH-SY5Y and PC-12 retain sensitivity to neurotoxic stimuli; however, their application depends on the specific pathology (Alzheimer's disease vs. Parkinson's disease). Conclusion. An optimal strategy for experimental modeling of neuroinflammation involves a multi-level approach: primary screening on standardized cell lines followed by validation on primary cultures, co-culture systems, and iPSC-derived cells. The presented critical analysis allows researchers to reasonably select the most appropriate cell model for specific tasks, taking into account its advantages and limitations, as well as the boundaries for translating the results to in vivo systems.
- 16 October 2026
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 3,p. 22-34
Open AccessApproaches to experimental modeling of neuroinflammation in neurodegenerative diseases: part 3 — cell lines
Background. Neuroinflammation is a key pathogenic mechanism in a wide range of central nervous system disorders, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and ischemic stroke. To study the molecular mechanisms of neuroinflammation and screen potential drug candidates, researchers have access to a wide arsenal of in vitro models. Immortalized cell lines remain an indispensable tool at the early stages of pharmacological research; however, their selection requires a critical evaluation of the advantages and limitations of each model. Objective. To conduct a critical analysis of the main immortalized cell lines of microglia, astrocytes, and neurons used for modeling neuroinflammation, and based on this analysis, to formulate recommendations for their selection depending on experimental objectives. Methods. A narrative literature review was performed, summarizing data on the origin, phenotypic characteristics, functional activity, and applications of cell lines. A comparative analysis was conducted for microglial lines (BV-2, N9, N13, EOC, HAPI, HMC3, HMO6), astrocytic lines (U-87, U-251, U-373, A-172, T98G), and neuronal lines (SH-SY5Y, PC-12), with emphasis on their response to inflammatory stimuli, mediator production, and preservation of specific markers. Results. The BV-2 line retains 90 % of genes induced in primary microglia and is considered the "gold standard" for primary screening of anti-inflammatory compounds; however, it exhibits an elevated basal activation level. Spontaneously immortalized lines EOC and HAPI/SIM-A9 are phenotypically closer to primary cells and retain functional phagocytosis. Among human lines, HMO6 demonstrates TREM2-dependent phagocytosis of β-amyloid and the ability for M1/M2 polarization, whereas HMC3 does not express key microglial markers (P2RY12, TREM2) and expresses pericyte markers, which significantly limits its value. Astrocytic lines differ in their sensitivity to IL-1β: U-251 and U-373 show a pronounced response, whereas T98G is resistant. Neuronal lines SH-SY5Y and PC-12 retain sensitivity to neurotoxic stimuli; however, their application depends on the specific pathology (Alzheimer's disease vs. Parkinson's disease). Conclusion. An optimal strategy for experimental modeling of neuroinflammation involves a multi-level approach: primary screening on standardized cell lines followed by validation on primary cultures, co-culture systems, and iPSC-derived cells. The presented critical analysis allows researchers to reasonably select the most appropriate cell model for specific tasks, taking into account its advantages and limitations, as well as the boundaries for translating the results to in vivo systems.
- 30 March 2026
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 1
Approaches to experimental modeling of neuroinflammation in neurodegenerative diseases: part 2 — genetic models
The use of genetic animal models plays a critical role in understanding the origin and biology of neuroinflammation and requires the involvement of pharmacology, neurobiology, immunology, and genetic engineering. Genetic models are crucial for mimicking particular molecular pathways of neuroinflammation and understanding the causal relationship between genotype, pathology, and behavior, that are impossible in postmortem or preclinical studies. Nowadays the majority of strategies for creating genetic models focused on reproduction of certain pathological processes — transgenic models with mutant form of human amyloid precursor protein (APP) or the presenilin 1 (PS1) gene (e.g. APP/PS1, 5xFAD, 3xTg-AD, PDAPP, APP23, Tg2576), transgenic models expressing human tau-protein (e.g. rTg4510, PS19, P301S), models targeting CNS immune cells (e.g. CX3CR1-GFP/+, hM3Dq/hM4Di (DREADD), Trem2 ko), and transgenic animal models with proinflammatory phenotype (e.g. IL-1β XAT , overexpression of p25, knockout of nerve growth factor (NGF)).
- 30 March 2026
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 1
Approaches to experimental modeling of neuroinflammation in neurodegenerative diseases: part 2 — genetic models
The use of genetic animal models plays a critical role in understanding the origin and biology of neuroinflammation and requires the involvement of pharmacology, neurobiology, immunology, and genetic engineering. Genetic models are crucial for mimicking particular molecular pathways of neuroinflammation and understanding the causal relationship between genotype, pathology, and behavior, that are impossible in postmortem or preclinical studies. Nowadays the majority of strategies for creating genetic models focused on reproduction of certain pathological processes — transgenic models with mutant form of human amyloid precursor protein (APP) or the presenilin 1 (PS1) gene (e.g. APP/PS1, 5xFAD, 3xTg-AD, PDAPP, APP23, Tg2576), transgenic models expressing human tau-protein (e.g. rTg4510, PS19, P301S), models targeting CNS immune cells (e.g. CX3CR1-GFP/+, hM3Dq/hM4Di (DREADD), Trem2 ko), and transgenic animal models with proinflammatory phenotype (e.g. IL-1β XAT , overexpression of p25, knockout of nerve growth factor (NGF)).
- Open Access
- 2 March 2026
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 4,p. 59-67
Approaches to experimental modeling of neuroinflammation in neurodegenerative diseases: part 1 — in vivo models
Given the increasing prevalence of the neurodegenerative diseases worldwide, the development of new methods for correction of neuroinflammation contributing to neurodegenerative diseases is a highly relevant and important issue in the field of biomedical research. Neuroinflammation experimental models are essential tools for developing novel therapies for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, multiple sclerosis sclerosis (ALS), epilepsy, and depression. Currently used models can generally be divided into in vitro and in vivo models or according to the method of action on the body – on chemical (exposure to neurotoxins and endogenous substances), genetic (transgenic and knockout animals), physical (injury, stress). Each of these experimental paradigms reproduce neuroinflammation in one aspect and not able to provide a complete picture of this complex process. Another problem is a lack of congruity between experimental model and clinical trials due to an unsuitable choice of the model, its unreliability or experiment conditions. This prevents the search of effective solutions for neurodegenerative disease treatment. Therefore, the current review aims to summarize the different experimental paradigms used to reproduce neuroinflammation and its main strengths and weaknesses, helping to choose the model that better suits each specific research aim.
- 2 March 2026
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 4,p. 59-67
Open AccessApproaches to experimental modeling of neuroinflammation in neurodegenerative diseases: part 1 — in vivo models
Given the increasing prevalence of the neurodegenerative diseases worldwide, the development of new methods for correction of neuroinflammation contributing to neurodegenerative diseases is a highly relevant and important issue in the field of biomedical research. Neuroinflammation experimental models are essential tools for developing novel therapies for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, multiple sclerosis sclerosis (ALS), epilepsy, and depression. Currently used models can generally be divided into in vitro and in vivo models or according to the method of action on the body – on chemical (exposure to neurotoxins and endogenous substances), genetic (transgenic and knockout animals), physical (injury, stress). Each of these experimental paradigms reproduce neuroinflammation in one aspect and not able to provide a complete picture of this complex process. Another problem is a lack of congruity between experimental model and clinical trials due to an unsuitable choice of the model, its unreliability or experiment conditions. This prevents the search of effective solutions for neurodegenerative disease treatment. Therefore, the current review aims to summarize the different experimental paradigms used to reproduce neuroinflammation and its main strengths and weaknesses, helping to choose the model that better suits each specific research aim.
- Open Access
- 23 May 2025
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 1,p. 43-52
The study of antiparkinsonian activity of the combination of ladasten with fabomotizole in paraquat-induced model of parkinsoian syndrome
Relevance. Parkinson's disease (PD) is a neurodegenerative disease characterized by motor impairments. The currently used antiparkinsonian pharmacotherapy, despite the symptomatic improvement of patients, is associated with severe side effects. The combination of ladasten with fabomotizole may have a potential neuroprotective effect in the neurodegeneration conditions observed in PD, due to its multitargeting action.Objective. The study explores the potential antiparkinsonian activity of a combination of ladasten and fabomotizole in paraquat-induced model of parkinsonian syndrome (PS).Methods. PS was modeled by intraperitoneal administration of paraquat (10 mg/kg) 1 time every 3–4 days for 21 days. The C57Bl/6 mice were divided into 4 groups: 1) passive control, 2) active control, 3) ladasten + fabomotizole combination, 4) levodopa. The animals were tested in the battery of behavioral tests each week of the experiment.Results. The combination of ladasten with fabomotizole successfully treated all manifestations of PS in the battery of behavioral tests, and the greatest difference compared with the active control was found in most tests on the 3rd week of the experiment. Thus, the combination increased latency to fall in the «rotarod test» by 2,38 (p < 0.0001) and 1.5 times (p < 0.01) at fixed and accelerating speed, decreased the turning and descent time in the «pole test» by 1.4 (p < 0.05) and 1.53 times (p < 0.001).Conclusion. The combination of ladasten with fabomotizole reduced the severity of paraquat-induced PS in the battery of behavioral tests, and it was comparable with the effects of levodopa.
- 23 May 2025
- Published by Publishing House OKI in Pharmacokinetics and Pharmacodynamics
- No. 1,p. 43-52
Open AccessThe study of antiparkinsonian activity of the combination of ladasten with fabomotizole in paraquat-induced model of parkinsoian syndrome
Relevance. Parkinson's disease (PD) is a neurodegenerative disease characterized by motor impairments. The currently used antiparkinsonian pharmacotherapy, despite the symptomatic improvement of patients, is associated with severe side effects. The combination of ladasten with fabomotizole may have a potential neuroprotective effect in the neurodegeneration conditions observed in PD, due to its multitargeting action.Objective. The study explores the potential antiparkinsonian activity of a combination of ladasten and fabomotizole in paraquat-induced model of parkinsonian syndrome (PS).Methods. PS was modeled by intraperitoneal administration of paraquat (10 mg/kg) 1 time every 3–4 days for 21 days. The C57Bl/6 mice were divided into 4 groups: 1) passive control, 2) active control, 3) ladasten + fabomotizole combination, 4) levodopa. The animals were tested in the battery of behavioral tests each week of the experiment.Results. The combination of ladasten with fabomotizole successfully treated all manifestations of PS in the battery of behavioral tests, and the greatest difference compared with the active control was found in most tests on the 3rd week of the experiment. Thus, the combination increased latency to fall in the «rotarod test» by 2,38 (p < 0.0001) and 1.5 times (p < 0.01) at fixed and accelerating speed, decreased the turning and descent time in the «pole test» by 1.4 (p < 0.05) and 1.53 times (p < 0.001).Conclusion. The combination of ladasten with fabomotizole reduced the severity of paraquat-induced PS in the battery of behavioral tests, and it was comparable with the effects of levodopa.
- 9 October 2024
- Published by Folium Publishing Company in Экспериментальная и клиническая фармакология
- Vol. 87 (9) , 9-14
Исследование антипаркинсонического действия комбинации ладастена с фабомотизолом на модели паркинсонического синдрома, вызванного 6-гидроксидофамином
Исследование посвящено изучению действия комбинации ладастена (10, 50, 100 мг/кг) и фабомотизола (5, 10 мг/кг) на модели паркинсонического синдрома у мышей, вызванного унилатеральным введением 6-гидроксидофамина. Установлена способность комбинации ладастена (50 и 100 мг/кг) с фабомотизолом (5 мг/кг) снижать выраженность двигательных проявлений паркинсонического синдрома в тестах «Вращающийся стержень» (в среднем в 3,2 раза (p < 0,0001) при постоянной скорости вращения стержня, при нарастающей скорости вращения — в 1,8 раза (p < 0,001)), «Вертикальный стержень» (время поворота в среднем в 1,4 раза (p < 0,05) и время спуска в 1,4 раза (p < 0,001)), «цилиндр» (использование контрлатеральной лапы в среднем составляло 43,8 % от общего числа контактов) и «длина шага» (увеличение длины шага передних лап в среднем на 1 см (p < 0,01), а задних — на 1,2 см (p < 0,001)). Комбинация ладастена (50 и 100 мг/кг) с фабомотизолом (10 мг/кг) приводила к снижению выраженности моторного дефицита (в среднем в 5 раз (p < 0,0001) при постоянной скорости вращения стержня и в 2 раза (p < 0,001) при нарастающей скорости вращения стержня), брадикинезии (время поворота сокращалось в среднем в 1,6 раз (p < 0,05) и время спуска — в 1,5 раза (p < 0,05)), акинезии передних конечностей (использование контрлатеральной лапы в среднем составляло 45,3 % от общего числа контактов) и изменение длины шага (увеличение длины шага передних конечностей в среднем на 0,6 см (p < 0,05), а задних лап — на 0,8 см (p < 0,05)).
- 9 October 2024
- Published by Folium Publishing Company in Экспериментальная и клиническая фармакология
- Vol. 87 (9) , 9-14
Исследование антипаркинсонического действия комбинации ладастена с фабомотизолом на модели паркинсонического синдрома, вызванного 6-гидроксидофамином
Исследование посвящено изучению действия комбинации ладастена (10, 50, 100 мг/кг) и фабомотизола (5, 10 мг/кг) на модели паркинсонического синдрома у мышей, вызванного унилатеральным введением 6-гидроксидофамина. Установлена способность комбинации ладастена (50 и 100 мг/кг) с фабомотизолом (5 мг/кг) снижать выраженность двигательных проявлений паркинсонического синдрома в тестах «Вращающийся стержень» (в среднем в 3,2 раза (p < 0,0001) при постоянной скорости вращения стержня, при нарастающей скорости вращения — в 1,8 раза (p < 0,001)), «Вертикальный стержень» (время поворота в среднем в 1,4 раза (p < 0,05) и время спуска в 1,4 раза (p < 0,001)), «цилиндр» (использование контрлатеральной лапы в среднем составляло 43,8 % от общего числа контактов) и «длина шага» (увеличение длины шага передних лап в среднем на 1 см (p < 0,01), а задних — на 1,2 см (p < 0,001)). Комбинация ладастена (50 и 100 мг/кг) с фабомотизолом (10 мг/кг) приводила к снижению выраженности моторного дефицита (в среднем в 5 раз (p < 0,0001) при постоянной скорости вращения стержня и в 2 раза (p < 0,001) при нарастающей скорости вращения стержня), брадикинезии (время поворота сокращалось в среднем в 1,6 раз (p < 0,05) и время спуска — в 1,5 раза (p < 0,05)), акинезии передних конечностей (использование контрлатеральной лапы в среднем составляло 45,3 % от общего числа контактов) и изменение длины шага (увеличение длины шага передних конечностей в среднем на 0,6 см (p < 0,05), а задних лап — на 0,8 см (p < 0,05)).
- 1 July 2021
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 43, 128055
Antibacterial activity of noscapine analogs
- 1 July 2021
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 43, 128055
Antibacterial activity of noscapine analogs
- 20 December 2017
- Published by Bentham Science Publishers Ltd. in Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
- Vol. 16 (2)
Anti-Inflammatory Activity of Novel 12-N-methylcytisine Derivatives
Neurodegenerative diseases and inflammation are always linked to each other; therefore the elaboration of new chemical compounds, which interact with pharmacological targets involved into these two processes, can become one of ways of correction of these types of human CNS pathology. In the field of this problem the anti-inflammatory activity of ten 3-amino derivatives of quinolizidine alkaloid (-)-cytisine (the data about nootropic activity of these compounds are outlined by us previously) was studied by using in vivo, in vitro and in silico approaches. It was established that ability of 3-(2-hydroxyphenyl)amino, 3-(4-hydroxyphenyl)amino and 3-(3-phenylprop-2-en-1-yl)amino derivatives of 12-N-metylcytisine to inhibit the carrageenan-induced paw oedema in rats is comparable with reference drug diclofenac. The results of in vitro COX-1/COX-2 inhibition assay showed no significant activity of tested compounds, except compounds with 2-hydroxyphenyl, 3-phenylprop-2-en-1-yl, furyl and thiophenyl fragments which slightly reduce the activity of COX-2. The results of molecular docking procedure allow assuming, that anti-inflammatory properties of the most active amines are due to their interaction with key amino acids and different ways of their accommodation in the COX-1/COX-2 active sites.
- 20 December 2017
- Published by Bentham Science Publishers Ltd. in Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
- Vol. 16 (2)
Anti-Inflammatory Activity of Novel 12-N-methylcytisine Derivatives
Neurodegenerative diseases and inflammation are always linked to each other; therefore the elaboration of new chemical compounds, which interact with pharmacological targets involved into these two processes, can become one of ways of correction of these types of human CNS pathology. In the field of this problem the anti-inflammatory activity of ten 3-amino derivatives of quinolizidine alkaloid (-)-cytisine (the data about nootropic activity of these compounds are outlined by us previously) was studied by using in vivo, in vitro and in silico approaches. It was established that ability of 3-(2-hydroxyphenyl)amino, 3-(4-hydroxyphenyl)amino and 3-(3-phenylprop-2-en-1-yl)amino derivatives of 12-N-metylcytisine to inhibit the carrageenan-induced paw oedema in rats is comparable with reference drug diclofenac. The results of in vitro COX-1/COX-2 inhibition assay showed no significant activity of tested compounds, except compounds with 2-hydroxyphenyl, 3-phenylprop-2-en-1-yl, furyl and thiophenyl fragments which slightly reduce the activity of COX-2. The results of molecular docking procedure allow assuming, that anti-inflammatory properties of the most active amines are due to their interaction with key amino acids and different ways of their accommodation in the COX-1/COX-2 active sites.
- 22 February 2017
- Published by Springer Nature in Medicinal Chemistry Research
- Vol. 26 (5) , 900-908
Synthesis and in vitro cytotoxicity evaluation of some N-substituted α-amino acid derivatives containing a hexahydropyrimidine moiety
- 22 February 2017
- Published by Springer Nature in Medicinal Chemistry Research
- Vol. 26 (5) , 900-908
Synthesis and in vitro cytotoxicity evaluation of some N-substituted α-amino acid derivatives containing a hexahydropyrimidine moiety
- 1 September 2015
- Published by Springer Nature in Chemistry of Natural Compounds
- Vol. 51 (5) , 910-915
Synthesis and Nootropic Activity of new 3-Amino-12-N-Methylcytisine Derivatives
- 1 September 2015
- Published by Springer Nature in Chemistry of Natural Compounds
- Vol. 51 (5) , 910-915
Synthesis and Nootropic Activity of new 3-Amino-12-N-Methylcytisine Derivatives